Mounjaro and thyroid problems: what the evidence says

You have hypothyroidism and want to know if Mounjaro is off the table

For most people with an underactive thyroid, Mounjaro is not automatically excluded. Hypothyroidism is actually one of the weight-related conditions that can support eligibility for treatment at a BMI of 27 or above, alongside the standard BMI threshold of 30. The practical concern your prescriber will raise is control: if your TSH is well outside range because your levothyroxine dose hasn't been reviewed recently, that alone can make weight loss harder and complicate any treatment. Sorting thyroid control first is the sensible sequence.

The other thing worth knowing is that Mounjaro slows gastric emptying, which is part of how it reduces appetite. Levothyroxine is sensitive to absorption conditions, it's normally taken on an empty stomach, well away from food and other medicines. The Mounjaro SmPC on the eMC doesn't list levothyroxine as a direct pharmacokinetic interaction, but clinicians generally advise keeping the two well separated in your morning routine to avoid any overlap in absorption. Your prescriber or GP can advise on exact timing for your situation. Our detailed breakdown of Mounjaro and thyroid issues covers this timing question in more depth.

Weight gain is a recognised symptom of uncontrolled hypothyroidism, so patients in this situation often come to us after years of struggling despite doing everything right. That context matters clinically and our prescribers take it seriously.

The contraindication that changes things: medullary thyroid carcinoma

This is the hard line. Tirzepatide (the active ingredient in Mounjaro) is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or who has Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is stated clearly in the SmPC and reflected in the BNF's tirzepatide entry. The reason goes back to animal studies: rodents given GLP-1 receptor agonists developed C-cell tumours at high doses. The clinical significance in humans at the doses used therapeutically is genuinely uncertain, but because MTC arises from thyroid C-cells, the precautionary position is an absolute contraindication for anyone with that history.

If you have had thyroid cancer of a different type (papillary, follicular, or anaplastic) this contraindication does not automatically apply. Those cancers don't originate in C-cells. Your prescriber still needs to know your history and may want to involve your oncologist or endocrinologist before approving treatment. Suitability in that scenario is individual, not a blanket yes or no. If you have had any thyroid surgery and now have no functioning thyroid, the picture is slightly different again, there's a separate page on taking Mounjaro with no thyroid that addresses that situation specifically.

Declaring your thyroid history accurately at consultation isn't just a formality. It's the part of the process that keeps you safe.

Hyperthyroidism, thyroid nodules, and other thyroid conditions

An overactive thyroid (hyperthyroidism or Graves' disease) doesn't appear as a named contraindication in the SmPC, but an uncontrolled hyperthyroid state can affect heart rate, bone density, and metabolic baseline in ways that a prescriber needs to factor into their assessment. Poorly managed hyperthyroidism and the cardiovascular effects of tirzepatide (modest reductions in resting heart rate are sometimes seen) warrant discussion with a clinician rather than a self-directed decision. Our page on Mounjaro and heart problems gives useful context on cardiovascular considerations, and if you are specifically wondering whether people with heart problems can take Mounjaro, that page walks through the key clinical factors in detail.

Thyroid nodules without a history of MTC are generally not a contraindication, though your prescriber may want to know whether they've been investigated and whether any follow-up is ongoing. Autoimmune thyroid conditions (Hashimoto's thyroiditis, for example) are managed primarily through thyroid hormone replacement; treatment with Mounjaro is assessed on the same basis as any hypothyroid patient once thyroid function is reasonably controlled.

The NHS guidance on tirzepatide safety considerations is a reliable starting point, but it isn't a substitute for a clinician reading your specific history. Weight management decisions sit at the intersection of several conditions at once, and the clinical team at nume is trained to hold that complexity. If you want to understand the process before starting, the consultation page sets out exactly what's involved.

What to expect from a clinical assessment at nume

Every consultation at nume is read by a GPhC-registered Independent Prescriber on the same day it's submitted, a real clinician, not automated triage. You'll be asked about your thyroid history, current medication, recent test results if relevant, and your broader health picture. If your thyroid is well controlled and there's no MTC history, approval for Mounjaro is entirely possible. If there are questions your prescriber can't resolve without input from your endocrinologist or GP, they'll say so plainly.

Once approved, your treatment is dispatched the same day if you order before 12pm Monday to Friday, arriving in plain unbranded packaging via DPD the next working day, you get a tracking link so you know exactly when to expect it. The pen itself is a pre-filled KwikPen; our overview of weight-loss treatment options explains the practical mechanics if you haven't used an injectable medicine before. If you are based in the north-west and want to know more about how we serve your area, our Mounjaro Liverpool page covers local availability and what to expect from the process there.

If you have questions before starting, our team is reachable seven days a week. Check your eligibility when you're ready to take the next step.